pacman schreef op 25 augustus 2021 11:33:
ICER Updates Assessment of Hereditary Angioedema Therapies
24 aug 2021,
The updated assessment shows the need for even larger price discounts to reach common thresholds for cost-effectiveness. ICER uses a benchmark it developed, the health-benefit price benchmark (HBPB), a price range suggesting the highest U.S. price a manufacturer should charge for a treatment based on the amount of improvement in overall health patients receive from that treatment.
The updated benchmark range for Takhzyro is now $218,900 to $219,800 per year, which would require about 53% discount off the treatment’s current U.S. list price. Previously, using only the data and assumptions from the randomized clinical trials, ICER’s 2018 health-benefit price benchmark for Takhzyro had been between $537,200 to $540,100.
For Haegarda, the range is now $247,700 to $248,800 per year, which would require a 54% discount off the treatment’s current U.S. list price. In 2018, ICER had a benchmark range of between $522,200 to $525,100.
For Cinryze, the updated benchmark range is $139,800 to $140,600 per year, which would require a 75% discount off the treatment’s current US list price. In 2018, HBPB for Cinryze had been between $307,500 to $309,300.